Pharma Equity Group: Market update
Pharma Equity Group made and reverse IPO earlier in 2023. The company is a Life Science investment company and the first investment is the wholly owned subsidairy Reponex Pharma. Reponex focus on repositioning drug candidates in phase ll and partnering for fase lll trials. Reponex pipeline consists of 6 candidates so far.
This interview with CEO Thomas K. Selso is a wrap-up of The Equity Story and events during 2023.
Listen here: Pharma Equity Group
Disclaimer: HC Andersen Capital receives payment from Pharma Equity Group for a Digital IR/Corporate Visibility subscription agreement. /Claus Thestrup 1:45 PM 12-12-2023.
Login required
This content is only available for logged in users
Pharma Equity Group
Pharma Equity Group develops new medicines for the local treatment of serious and life-threatening inflammatory diseases for which there is currently no adequate treatment. The company uses repositioning of existing drugs and brings drug candidates to a clinical phase III stage, after which it is handed over to a strategic partner who will complete the development of the products and bring them to market, either independently or in collaboration with the company.
Read more on company page